[go: up one dir, main page]

MX2012002608A - Compuesto 1,2-dihidro -2-oxoquinolona como ligandos del receptor 5ht4. - Google Patents

Compuesto 1,2-dihidro -2-oxoquinolona como ligandos del receptor 5ht4.

Info

Publication number
MX2012002608A
MX2012002608A MX2012002608A MX2012002608A MX2012002608A MX 2012002608 A MX2012002608 A MX 2012002608A MX 2012002608 A MX2012002608 A MX 2012002608A MX 2012002608 A MX2012002608 A MX 2012002608A MX 2012002608 A MX2012002608 A MX 2012002608A
Authority
MX
Mexico
Prior art keywords
dihydro
compounds
receptor ligands
present
oxoquinoline
Prior art date
Application number
MX2012002608A
Other languages
English (en)
Inventor
Venkateswarlu Jasti
Ramakrishna Nirogi
Pradeep Jayarajan
Gopinadh Bhyrapuneni
Abdul Rasheed Mohammed
Ishtiyaque Ahmad
Najaraj Vishwottam Kandikere
Anil Karbhari Shinde
Rama Sastri Kambhampati
Jyothsna Ravula
Sriramachandra Murthy Patnala
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2012002608A publication Critical patent/MX2012002608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención se relaciona con nuevos compuestos 1,2-dihidro-2-oxoquinolina de fórmula (I) y con sus derivados, profármacos, tautómeros, estereoisómeros, polimorfos, solvatos, hidratos, metabolitos, N-óxidos, sales farmacéuticamente aceptables y composiciones que los contienen. Fórmula (I). La presente invención también se relaciona con un proceso para la preparación de los nuevos compuestos ya mencionados y de sus derivados, profármacos, tautómeros, estereoisómeros, polimorfos, solvatos, hidratos, metabolitos, N-óxidos, sales farmacéuticamente aceptables y composiciones que los contienen. Los compuestos de la presente invención son útiles en el tratamiento y/o prevención de varios trastornos en los que interviene la actividad del receptor 5HT4.
MX2012002608A 2009-09-14 2009-12-29 Compuesto 1,2-dihidro -2-oxoquinolona como ligandos del receptor 5ht4. MX2012002608A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2224CH2009 2009-09-14
PCT/IN2009/000745 WO2011030349A1 (en) 2009-09-14 2009-12-29 L -dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands

Publications (1)

Publication Number Publication Date
MX2012002608A true MX2012002608A (es) 2012-04-02

Family

ID=42126528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002608A MX2012002608A (es) 2009-09-14 2009-12-29 Compuesto 1,2-dihidro -2-oxoquinolona como ligandos del receptor 5ht4.

Country Status (16)

Country Link
US (1) US8598204B2 (es)
EP (1) EP2507225B1 (es)
JP (1) JP5540099B2 (es)
KR (1) KR101386354B1 (es)
CN (1) CN102639526B (es)
AU (1) AU2009352490B2 (es)
CA (1) CA2771885C (es)
DK (1) DK2507225T3 (es)
EA (1) EA020227B1 (es)
ES (1) ES2578628T3 (es)
IL (1) IL218525A (es)
MX (1) MX2012002608A (es)
NZ (1) NZ598505A (es)
SG (1) SG178557A1 (es)
WO (1) WO2011030349A1 (es)
ZA (1) ZA201201429B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329909B2 (en) * 2009-04-24 2012-12-11 Nissan Chemical Industries, Ltd. Method for producing 2-azaadamantane compound from bicyclocarbamate compound
KR20120044978A (ko) 2009-06-19 2012-05-08 아보트 러보러터리즈 디아자호모아다만탄 유도체 및 이들의 사용 방법
AU2012367780B2 (en) * 2011-12-22 2017-04-06 Connexios Life Sciences Pvt. Ltd. Derivatives of aza adamantane and uses thereof
RU2557249C1 (ru) * 2014-03-03 2015-07-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный технический университет" Способ получения 1-гидрокси-4-адамантанона
CN106957252B (zh) * 2014-11-19 2019-11-19 连云港恒运药业有限公司 一种质子泵抑制剂中间体及其制备方法
CN111386127A (zh) 2017-11-30 2020-07-07 阿拉基斯医疗公司 核酸结合光探针和其用途
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
CN115677567A (zh) * 2022-11-15 2023-02-03 大唐环境产业集团股份有限公司 一种4-氨基-1-哌啶丙醇的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008965A1 (en) 1992-10-16 1994-04-28 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
JPH07324087A (ja) * 1994-04-04 1995-12-12 Taisho Pharmaceut Co Ltd 複素環化合物
US7405235B2 (en) * 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
ATE441646T1 (de) 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
MX2007007818A (es) 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
ES2366375T3 (es) 2005-02-22 2011-10-19 Pfizer, Inc. Derivados de oxiindol, como agonistas del receptor 5-ht4.
ES2523459T3 (es) 2005-02-25 2014-11-26 Raqualia Pharma Inc Derivados de benzisoxazol
NZ560828A (en) * 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
ATE449092T1 (de) 2005-07-22 2009-12-15 Pfizer Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
US8557994B2 (en) * 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives

Also Published As

Publication number Publication date
EA201270421A1 (ru) 2012-09-28
CA2771885A1 (en) 2011-03-17
ZA201201429B (en) 2012-10-31
CA2771885C (en) 2014-04-08
US20120277216A1 (en) 2012-11-01
KR101386354B1 (ko) 2014-04-16
JP5540099B2 (ja) 2014-07-02
JP2013504561A (ja) 2013-02-07
CN102639526A (zh) 2012-08-15
KR20120081986A (ko) 2012-07-20
WO2011030349A1 (en) 2011-03-17
AU2009352490A1 (en) 2012-04-19
CN102639526B (zh) 2014-06-04
SG178557A1 (en) 2012-03-29
EA020227B1 (ru) 2014-09-30
EP2507225A1 (en) 2012-10-10
NZ598505A (en) 2013-01-25
AU2009352490B2 (en) 2013-06-20
ES2578628T3 (es) 2016-07-28
IL218525A (en) 2014-12-31
HK1173140A1 (en) 2013-05-10
US8598204B2 (en) 2013-12-03
DK2507225T3 (en) 2016-07-04
IL218525A0 (en) 2012-07-31
EP2507225B1 (en) 2016-06-01

Similar Documents

Publication Publication Date Title
MX2012002608A (es) Compuesto 1,2-dihidro -2-oxoquinolona como ligandos del receptor 5ht4.
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
MX2012000231A (es) Nuevos aza-biciclo-hexanos.
PH12014500855A1 (en) Novel substituted imidazopyrimidines as gpbar1 receptor modulators
MX2009005252A (es) Aminopirrolidinas como antagonistas del receptor de quimiocina.
PH12015501199B1 (en) Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
MY183373A (en) Pyridine and pyrazine derivatives as protein kinase modulators
TW200833675A (en) Nicotinamide derivatives
PH12013501557A1 (en) Glucagon receptor modulator
WO2009093269A9 (en) Novel heterocyclic compounds
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MX2013005833A (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
WO2013038429A3 (en) Novel sglt inhibitors
MX2012006909A (es) LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA.
MX337721B (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
WO2012172566A3 (en) Novel sglt inhibitors
UA98772C2 (ru) Производные циклопропиламина как модуляторы н3-гистаминового рецептора
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
MX2012007783A (es) Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
MX2013006768A (es) Moduladores de receptor de glucagon.
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
EA201270556A1 (ru) Конденсированные тиазоло и оксазолопиримидиноны
NZ600536A (en) Bicyclic compounds as alpha4 beta2 nicotinic acetylcholine receptor ligands

Legal Events

Date Code Title Description
FG Grant or registration